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The relative tissue content of dystrophin has been evaluated in the slow-twitch soleus (primarily type 1 fibers) and fast-twitch vastus lalaralis 
(primarily type Ilb filbers) muscles of the rat and mouse, as well as in human biopsy samples from the va~tus lateralis and gluteus maximus muscles. 
using a sensitive immunochemical assay, The dystrophin content of the soleus muscle was approximately twofold higher than in the vastus lateralis 
muscle, This difference is not entirely explained by the higher total sarcolemmal surface of the smaller soleus muscle type I fil~rs, and is therefore 
attributed to a higher content of dystrophin in the type I fibers compared to type llb fibers, Peg  analysis of the dystrophin transcript levels in 
the two muscle types indicated no significant differences. Analysis of human muscle biopsies revealed a tv~ofold higher dystrophin content in the 
vastus lateralis muscle compared to the gluteus maximum muscle, It is concluded that the tissue content ofdystrophin may vary significantly among 
physiologically different skeletal muscle types, 
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1. INTRODUCTION 
Dystrophin, the protein product of  the human Duch- 
enne and Becker muscular dystrophy (DMD/BMD) 
gen~ [I], is a large, 427 kDa membrane-associated ey- 
toskeletal protein [2-5]. A significant effort has been 
devoted to the study of the cellular, molecular and ge- 
netic aspects of this inherited human muscular disorder, 
yet the precise cellular function,s) of this protein, whose 
absence results in a degenerative r sponse in the muscle 
fiber, is not clear. 
A curious feature of the dystrophic condition in both 
humans (DMD) and mice (mdx) is the possible early 
and preferential involvement of specific muscle fiber 
types in the degenerative process. Using an antibody 
against an isoform of alpha-actinin as a specific probe 
for type lib muscle fibers Minetti et al. [6] have recently 
provided convincing evidence for the early and prefer- 
ential degeneration f this particular fiber type in DMD 
patients. Webster and colleagues [7] have concluded 
that regeneration of type lib fibers occurs before slow 
(i.e. type I) fibers are even affected by the disease. These 
investigators therefore suggested that dystrophin may 
have a specific function in type lI fibers, which are 
capable of relatively higher rates of contraction com- 
pared to type I fibers. Hoffman and Gorospe [8] have 
presented an attractive interpretation for the observed 
differences between the effect of DMD on different fiber 
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types based on the various factors which are involved 
in cellular calcium homeostasis. 
Despite a lack of definitive xperimental evidene¢ in- 
dicative of a specific and early fiber-type involvement 
in the degenerative process characteristic of muscular 
dystrophy it is noteworthy that mdx muscle fibers are 
more vulnerable to necrosis, induced by lengthening 
contractions, compared to normal animals [9]. This ob- 
servation is of particular significance in view of reports 
indicating that fast-twitch muscle fibers are preferen- 
tially damaged by eccentric ontractions [10,11]. That 
a specific skeletel muscle fiber-type is more or less sus- 
ceptible to the effects of dystrophin deficiency remains 
an open question which warrants further investigation. 
The objective of the present series of experiments has 
been to quantitatively evaluate the relative amount of 
dystrophin and its corresponding mRNA transcript in 
the slow-twitch soleus (SOL) and superficial portion of 
the fast-twitch vastus lateralis (SVL) muscles of the rat 
and mouse. Relative dystrophin content was also deter- 
mined in biopsy samples from human vastus lateralis 
and sluteus maximus (GM) muscles. 
2. MATERIALS AND METHODS 
2.1. Tic'sue homogetu~tes 
The SOL and $VL were dish.ted from C$7BL 105 % female mi¢¢ 
and Sprague-Dawley rats, snap-frozen in liquid nitrogen and stored 
at -80"C until use. Tissue homogenization was carried out in I0 vols. 
of sample buffer (10 mM Tris, pH 8,0. I mM EDTA, 3.3% SDS, 10% 
/~lycerol at~d 40 MM dithiolhreitol) supplem.~t~ ::';.th a pro! ~ease 
inhibitor combination [12], The human muscle tissue wa~ obtained by 
surgical biopsy and immediately prepared for eleetrophoretic anal~is 
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[12], The mass of total protein in the tissue homogenates was deter- 
mined by the filter paper dye.binding technique [13], 
2,2, Gel eleetrophoresis and quanfifieation f immunoreaetion products 
The tissue ~..mples containing 10 pg of protein were subjected to 
SDS-PAGE electrophoresis according to the method of Laemmli [14] 
with the following modifications [12], A 7-15% linear gradient resolv- 
ing gel and a 6% stacking el were used. The ratio of acrylamide to 
bisacr:),lamide was 30:0,15 in the stock solution. Electrophoresis was 
performed ina minigel apparatus (Bio-Rad, Canada) with I ram-thick 
spa~rs, and fractionated proteins were electroblotted onto polyvi- 
nylidene membranes (Millipore Corp,, Canada) using a Bio-Rad mini- 
transblot cleetrophorctie ransfer cell. Two monoclonal ntibodies to 
dystrophin were obtained from Novocastra Laboratories Ltd,, 
(Ne~veastl= upon Tyne, England), These particular antibodies, desig- 
nated NCL-DYS 1 and NCL-DYS 2, are direEted against the mid-rod 
domain (amino acids 1,181-1,388) and a synthetic peptide correspond- 
ing to the last 17 amino acids of the C-terminal region, respectively, 
o1" the human dystrophin sequence. The sEEondary antibody was an 
affinity-purified goat antl-mouse lgG conjugated to alkaline phos- 
phatase, and was dilutcd 1:10,000 (BIO/CAN SEiEntifiE, Canada). The 
antigen-antlbody complex was revealed by Ehronao~eni¢ dEvElopmEnt 
using 5.bromo-4-chloro-3 indolyl phosphate and nitroblue tetra- 
zolium (BCIP/N BT), 
The dystrophin immunoreaction product, the myosin heavy chain 
subunit of stained gels and stained post-transfer gels were digitized 
using the Louts Associates Research Analysis System (Amersham 
Corp,. Canada). The digitized images were quantitatively analysed 
using the GL 1000 program, Values are expressed as integrated optical 
density (IOD) and are corrected for background, The relative levels 
of dystrophin in ~tmples were standardized according to the mass of 
protein loaded into each gel lane, the quantity of the myosin heavy 
chain subunit n the pre- and post-tranffer gels, Each method of 
standardization gave identical results, 
2.3. l.s'olattot~ of RNA 
Total RNA was isolated from rat skeletal muscle tissue according 
to Chomczynski and Sacchi [15], and quantified spectrophotometri- 
cally by absorbanc¢ at260 am, 
2.4. Reverse transcriptase ( RT) and polymerase chain reaction ( PCR ) 
The oligonueleotide primers d scribed b~, Tanaka and Ozawa [16] 
were synthesized using a Biosearch model 8700 DNA synthesizer 
(New Brunswick Scientific), The primers, identical (5'TGAAATAA- 
TGGAGGAGAGACTCGG3') and complementary (5'GCAGGCC- 
ATTCC'i'CTTTCAGGAAA3') to the mouse DNA, corresponded to 
nueleotides 3,124--3,147 and 3,415-3,438, respectively, of human 
eDNA [17], Oligonueleotides were purified on a 7 M urea/15% poly- 
ac~lamide gels, The predicted length of the amplification product was 
314 base pairs [16]. 
RT and PCR were carried out as previousl:), described [18] in an 
automatic DNA thermal eyelet (Perkin-Elmer, Cetus, Norwalk, CT), 
Briefly, total RNA was mixed (total volume of 20/.tl) with a solution 
containing 100 tag of complementary primer, PCR buffer Ix, 1 mM 
of each of dN'fP.~ (Pharmaeia-LKB Ltd.), 40 U of RNAsita (Promcga 
Biotech Inc,) and 20 U of RAV2 revErsE transcriptase (Amersham 
Corp,), The resulting eDNA was either used undiluted, or serially 
diluted in water, and then used as the substrate forthe PCR reactions, 
The eDNA solutions (total volume of 200/.tl) were supplemented with 
500 ng each of the identical and complementary primers, 0,2 mM o1" 
eaEh dNTP, PeR buffer Ix and ~ U of Taq polymerase (Perkin-Elmcr, 
Colas). The amplification was carried out for 15 and 20 eyEles as 
previously described [18], 
To d~'tat'mine the size of the I'~R produc.ts, 20 ~1 of eaEh reaction 
sample was run with DNA markers fDNA ladder, Bethesda Research 
Laboratories) on 1,5% agarose gels, which were subsequently stained 
with ethidium bromide. The PCR products in the agarose gel were 
blotted onto Hybond.N membranes (Amersham Corp.) and then hy. 
bridized with a specific oligonucleotide probe (5'GCACCTTCA- 
GAAATATOCCAG3'), This probe is located between the two prim- 
ers and corresponds tonucleotides 3,224-3,255 of the human cDNA 
sequence, The probe was labelled with [y-~"P]ATP using T4 polynucle- 
otide kinase. Negative controls consisted of samples in which th= 
reverse transcriptase r action was omitted, The intensity of" the devel- 
oped signals on the autoradiograms was analysed quantitatively by 
image analysis as described for the immunoblottingexperiments, The 
bands on the membrane corresponding to the hybridization bands 
were excised, and radioactivity measured by liquid scintillation spec- 
trometry,, Background radioactivity was determined using unexposed 
areas of the membrane. 
3. RESULTS 
3.1. hnmunochemieal specificity of  D YS I and D YS 2 
The e lec t rophoret i c  p ro te in  prof i les ot" the muscle ho-  
mogenates  and  the  immunochemica l  specif ic ity o f  the 
two monoc lona l  ant ibod ies  d i rected aga inst  dys t roph in  
are shown in F ig.  1. Th is  par t i cu la r  SDS-PAGE s~cstem 
prov ides  a s igni f icant degree o f  reso lut ion o f  the very 
high molecu lar  mass  prote ins  o f  skeletal  muscle.  In al l  
muscle t issue homogenates  the DYS I ant ibody  reacts  
with dyst roph in ,  as well  as  with a prote in  o f  s l ight ly  
h igher  e lec t rophoret i c  mobi l i ty ,  whereas the ant ibody  
DYS 2 recognizes on ly  the dyst roph in  band (Figs. 1 and  
2), 
3.2. Quantification o f  dystrophin 
The re lat ive levels of' dys t roph in  were determined in 
the SOL  and  SVL muscles o f  the rat  and  mouse using 
a 13 
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Fig, 1, lmmunoehemieal specificity ofdystrophin antibodies. The pro- 
tein profiles of the human and rodent muscle tissue (V, vast us lateralis; 
S, solcus; (3, gluteus maximus) homogenates are illustrated in panel 
a, Antibody DYS t recognizes d),strophin, as well as a protein of 
higher electrophoretie mobility, while antibody DYS 2 tenets peEifi- 
cally and only with dystrophin (panel b). T, titin; N, nebulin; DYS, 
dystrophin; MHC, myosin heavy Ehain subunit, ;t-A, alpha-actinin; 
A, aetin. 
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Fig, 2. lmmunochemieal quantification of dystrophin in rat. mouse and human skeletal muscles, An example of the immunoblots using antibodies 
DYS I and DYS 2 are shown in panels a and e, reslxctively, with the corresponding relative quantification (IOD, integrated optical density units) 
provided in panels b and e. Values represent the means + SD of four separate xperiments or *four determinations i  the ease of the human biopsy 
samples. The myosin heavy chain subunit (MHC) region of a stained post-transfer $¢1 is ~ltown for reference (dL 
a quantitative immunoblotting method escribed previ- 
ously [12]. In both rat and mouse the dystrophin content 
is approximately twofold greater in the SOL muscle 
compared to the SVL muscle (Fig. 2). This result was 
obtained using either of the two monoclonal ntibodies, 
However, relative tissue content of the lower molecular 
weight protein recognized by the antibody DYS 1 does 
not vary significantly between the two muscles (Fig. 2e). 
Dystrophin was also immunoassayed using DYS 1 
and DYS 2 in two human muscle biopsy samples, It was 
found that the SVL muscle has approximately a twofold 
greater dystrophin level than the GM muscle, while the 
content of the lower molecular weight protein detected 
with DYS 1 does not differ significantly between the two 
muscles (Fig. 2e). 
3.3. Analysis of dystrophhz trat~script levels 
Having demonstrated that the relative tissue levels of
dystrophin varied up to twofold between the slow. 
twitch SOL and fast-twitch SVL muscles the second 
objective was to determine if the observed ifferences in 
protein content could be accounted for by differences in 
the cellular levels of the dystrophin transcript, In the 
first series of experiments otal RNA was serially di- 
luted (0.01, 0. L, 1.0, 2.0 and 3.0/zg) prior to RT. The 
eDNA derived from the RT was used as substrate for 
PCR, and the amplification reaction was carried out in 
the same tube. These experiments revealed that there is 
no significant difference between the two muscles with 
respect to the relative levels of dystrophin mRNA (Fig. 
3a and b). 
To further verify the accuracy of the quantification 
of the PCR products a second and alternative series of 
experiments were undertaken wherein a fixed amount 
of total RNA was used in the RT reaction and the 
resulting eDNA was serially diluted prior to the PCR 
reaetion. The results of these experiments i dicate that 
similar dystrophin transcript levels are found in mouse 
SOL and SVL muscles (Fig. 3e and d). 
4. DISCUSSION 
The results of the experiments reported here demon- 
strate that the cellular content of dystrophin isapprox- 
imately twofold greater in the SOL muscle of the rat and 
mouse compared to the SVL muscle. The rat SOL is 
composed primarily of type I fibers while the SVL is 
primarily type IIb fibers [19]. Using published ata for 
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Fig. S. Analysis ofdystrophin mRNA ievels in rat soleus (S) and vastus lateralis (V) muscles b~/PCR. The PCR products obtained following serial 
dilution of the template RNA are visualized inthe ethidium bromide-stained agarose gel following 20 cycles or amplification (panel a), and in the 
corresponding autoradiogram (panel b) following hybridization with a specific oligonueleotide probe. The PCR products of a second experiment 
using serially diluted eDNA are shown in panel ¢, with the corresponding autoradiogram in panel d. The exposure times of 24 h and 2 h correspond 
to 15 and 20 cycles of amplification, respectively, C- indicates a control where th RAV2 was omitted. RNA* indicates the corresponding mass 
of RNA in the PCR reaction following dilution or the eDNA. 
percent fiber-type composition and mean cross-sec- 
tional areas of the fibers in the two muscle types [20] and 
our data for the mouse muscles (unpublished results), 
we predicted that the SOL muscle of both the rat and 
mouse would contain a 40% greater content of dystro- 
phin than the SVL muscle. The validity of this calcula- 
tion is based on the assumption that the cellular distri- 
bution of dystrophin is uniform in both fiber types and 
restricted to the cytoplasmic face of the sarcolemma. 
This leaves approximately 60% of the observed iffer- 
ence in dystrophin content unaccounted for. We there- 
fore concluded that rodent type I fibers contain higher 
cellular quantities of dystrophin than type lib fibers. 
Furthermore, recent results obtained using various 
other antibodies indicate that fiber-type specific differ- 
ences in the cellular content of cytoskeletal proteins arc 
not restricted to dystrophin (unpublished observations). 
Several other investigations have revealed that filamin, 
spectrin and vinculin are found in greater quantities in 
avian slow muscle fibers than in fast muscle fibers [21-- 
23]. Based on the data presented here, and on the obser- 
vations of  other studies, it is tempting to speculate that 
the greater ability of slow-twitch muscle compared to 
fast-twitch muscle to maintain force over time [24] may 
be functionally related to differences ineytoskeletal pro- 
tein content. 
The protein of lower molecular weight detected by the 
DYS 1 antibody probably corresponds to the putative 
dystrophin isoform identified by Byers et al. [25] which 
lacks a portion of the C-terminus region of  the mole- 
cule. Since the DYS 2 antibody employed in the present 
study was generated using a synthetic peptide corre- 
sponding to the last 17 residues of the dystrophin se- 
quence it would not be expected to react with this partic- 
ular isoform (Fig. 2e). Efforts are currently underway 
to positively identify this putative dystrophin isoform, 
since the relative cellular abundance of this polypeptide 
does not show fiber-type specific differences that would 
be expected of a protein which, like dystrophin, is re- 
stricted to the fiber periphery [26]. 
The finding that fibers from human SVL muscle con- 
.*.ain twice as much dystrophin compared to fibers in the 
GM muscle was unexpected in view of several previous 
reports suggesting that the levels of dystrophin are 
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probably similar in all types of human skeletal muscles 
[27]. We attribute the detection of this difference to 
improved quantitative immunoblotting methodology 
for dystrophin [12]. The biopsy samples used in these 
experiments were taken from two skeletal muscles 
which are known to possess a similar range of propor- 
tions of type I and II fibers in humans [28], However, 
the diameter of human type l and II fibers can vary 
significantly [28], which may partially account for the 
observations reported here. It therefore remains to be 
clearly determined if a significant difference in the cellu- 
lar content of dystrophin exists between type 1 and type 
II fibers in humans. Nevertheless, these results may 
have important implications for the interpretation of 
immunoblotting tests in Becker muscular dystrophy 
(BMD), and for the analysis of female carriers whose 
muscle fibers may show a mosaic expression of dystro- 
phir.. It is generally accepted that the clinical severity of 
BMD is more closely correlated with e relative quan- 
tity of dystrophin than dystrophin quality [27,29]. The 
data presented here using the human muscle biopsy 
samples uggest that a comprehensive investigation of 
this aspect of dystrophin analysis could probe to be 
important with respect o clinical diagnostic proce- 
dures. 
The relative levels of the dystrophin transcript in the 
mouse SOL and SVL evaluated by RT-PCR were not 
significantly different. In view of the clear difference in 
the levels of the dystrophin protein in these two muscles, 
the data concerning dystrophin transcript levels could 
indicate that other control mechanisms operating, per- 
haps, on the translational process erve to regulate the 
intracellular levels of dystrophin. This information 
should be carefully considered when the relative levels 
of dystrophin and the corresponding transcripts are to 
be evaluated for quantitative purposes. 
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